Humanwell Healthcare (Group) Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker reported to be useful for the treatment of cancer, rheumatoid arthritis, renal disorders, multiple sclerosis, alopecia areata, urticaria, psoriasis and chronic obstructive pulmonary disease (COPD), among others.

Pierre Fabre SA has divulged serine/threonine-protein kinase B-raf (BRAF) inhibitors reported to be useful for the treatment of cancer.

Researchers at Children’s Hospital of Fudan University, Shanghaitech University and Suzhou Zhongke New Drug Incubator Biomedical Technology Co. Ltd. have identified WD repeat-containing protein 5 (WDR5; BIG3)/c-Myc interaction inhibitors reported to be useful for the treatment of cancer.

Chengdu Tetrahedral Drug Research Co. Ltd. has synthesized bicyclic derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infection.

Astrogen Co Ltd. has disclosed prodrugs of 5-aminolevulinic acid (5-ALA) derivatives acting as fluorescence imaging agents and photosensitizers in photodynamic therapy with improved storage stability, reported to be useful for diagnosis and treatment of cancer, aging, alopecia, insomnia, inflammatory and metabolic disorders.

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Zhejiang University have jointly discovered N2-3-fluoro-5-substituted phenyl-2-aminopyrimidine derivatives.

Work at the Chinese University of Hong Kong has led to the identification of bilobalide derivatives reported to be useful for the treatment of cancer, Alzheimer’s and Parkinson’s diseases.

The Council of Scientific and Industrial Research (India) has synthesized new benzo[de]isoquinoline-1,3-dione-based fluorophore probes acting as decaprenylphosphoryl-β-D-ribose oxidase (DprE1) (M. tuberculosis) inhibitors reported to be useful for the diagnosis and treatment of tuberculosis.

Boehringer Ingelheim Pharma GmbH & Co. KG patents describe piperidinylpyridinylcarbonitrile derivatives acting as glutaminyl-peptide cyclotransferase (QPCT; QC) and glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors.

Kind Pharmaceuticals LLC has patented substituted benzocyclobutene compounds acting as erythropoietin (EPO) production inhibitors reported to be useful for the treatment of cancer and polycythemia.